Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 25Rectal Neoplasms 23Esophageal Neoplasms 22Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 16Pancreatic Neoplasms 14Lung Neoplasms 14Head and Neck Neoplasms 12Colorectal Neoplasms 11Sarcoma 10Brain Neoplasms 10Neoplasms 9Colonic Neoplasms 8Adenocarcinoma Of Esophagus 7Melanoma 6Glioma 6Esophageal Squamous Cell Carcinoma 6Ovarian Neoplasms 5Oropharyngeal Neoplasms 5Hypopharyngeal Neoplasms 5Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5Prostatic Neoplasms 4Mouth Neoplasms 4Gliosarcoma 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Squamous Cell 4

Interventions

Carboplatin 79pembrolizumab 64Paclitaxel 64Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × Surgical Procedures, Operative × Clear all
NCT04770272 2026-01-12

neoMono

Palleos Healthcare GmbH

Phase 2 Terminated
442 enrolled 42 charts
Breast

Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡